Luther King Capital Management (LKCM)
FSTX

Luther King Capital Management (LKCM)’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,795
Closed -$239K – 523
2017
Q1 		$239K Buy
+7,795
New +$267K ﹤0.01% 475

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Luther King Capital Management (LKCM)'s FSTX Position: Q2 2017 in Review

Luther King Capital Management (LKCM) sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2017, closing a stake of 7,795 shares — an estimated $239K sold.

Luther King Capital Management (LKCM) first reported a position in FSTX in Q1 2017 and held it in 1 quarter. The position peaked at $239K in Q1 2017. 33 funds tracked by Wall St. Rank hold FSTX as of Q2 2017.

  • Luther King Capital Management (LKCM) reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 7,795 F-star Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $239K.
  • Luther King Capital Management (LKCM) first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Luther King Capital Management (LKCM)'s F-star Therapeutics, Inc. Common Stock position peaked at $239K in Q1 2017.
  • 33 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q2 2017, filed 10 Aug 2017.